BR112022003812A2 - Dispersão sólida amorfa, produto, e, métodos para administrar um ingrediente farmacêutico ativo a uma pessoa ou animal não humano e para formar uma dispersão sólida amorfa de um ingrediente farmacêutico ativo - Google Patents
Dispersão sólida amorfa, produto, e, métodos para administrar um ingrediente farmacêutico ativo a uma pessoa ou animal não humano e para formar uma dispersão sólida amorfa de um ingrediente farmacêutico ativoInfo
- Publication number
- BR112022003812A2 BR112022003812A2 BR112022003812A BR112022003812A BR112022003812A2 BR 112022003812 A2 BR112022003812 A2 BR 112022003812A2 BR 112022003812 A BR112022003812 A BR 112022003812A BR 112022003812 A BR112022003812 A BR 112022003812A BR 112022003812 A2 BR112022003812 A2 BR 112022003812A2
- Authority
- BR
- Brazil
- Prior art keywords
- active pharmaceutical
- pharmaceutical ingredient
- solid amorphous
- amorphous dispersion
- dispersion
- Prior art date
Links
- 239000008186 active pharmaceutical agent Substances 0.000 title abstract 7
- 239000006185 dispersion Substances 0.000 title abstract 6
- 239000007787 solid Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- -1 poly(acrylic acid) Polymers 0.000 abstract 8
- 239000007962 solid dispersion Substances 0.000 abstract 5
- 229920002125 Sokalan® Polymers 0.000 abstract 4
- 239000007788 liquid Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 238000001704 evaporation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
dispersão sólida amorfa, produto, métodos para administrar um ingrediente farmacêutico ativo a um animal não humano e para formar uma dispersão sólida amorfa de um ingrediente farmacêutico ativo, e, uso da dispersão sólida amorfa. trata-se de uma dispersão sólida amorfa que inclui um poli(ácido acrílico) linear e um ingrediente farmacêutico ativo. o poli(ácido acrílico) linear usado para formar a dispersão sólida amorfa tem uma viscosidade brookfield de pelo menos 100 cp a 25 °c. um método de formação de tal dispersão sólida amorfa de um ingrediente farmacêutico ativo inclui formar uma dispersão líquida de um poli(ácido acrílico) linear, um ingrediente farmacêutico ativo, e um sistema de solvente, em que o poli(ácido acrílico) linear tem uma viscosidade brookfield a 25 °c de pelo menos 100 cp, e evaporar o sistema de solvente da dispersão líquida para formar uma dispersão sólida amorfa
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962892679P | 2019-08-28 | 2019-08-28 | |
PCT/US2020/048429 WO2021041824A1 (en) | 2019-08-28 | 2020-08-28 | Drug-polymer amorphous solid dispersions using linear poly (acrylic acid) polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022003812A2 true BR112022003812A2 (pt) | 2022-05-24 |
Family
ID=72433073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022003812A BR112022003812A2 (pt) | 2019-08-28 | 2020-08-28 | Dispersão sólida amorfa, produto, e, métodos para administrar um ingrediente farmacêutico ativo a uma pessoa ou animal não humano e para formar uma dispersão sólida amorfa de um ingrediente farmacêutico ativo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220304936A1 (pt) |
EP (1) | EP4021416A1 (pt) |
JP (1) | JP2022546411A (pt) |
KR (1) | KR20220054311A (pt) |
CN (1) | CN114302710A (pt) |
AU (1) | AU2020336471A1 (pt) |
BR (1) | BR112022003812A2 (pt) |
CA (1) | CA3152307A1 (pt) |
IL (1) | IL290943A (pt) |
MX (1) | MX2022002280A (pt) |
WO (1) | WO2021041824A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0904060B1 (en) * | 1996-05-20 | 2003-12-10 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
JP5646340B2 (ja) | 2007-12-12 | 2014-12-24 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | ポリマー性対イオンと活性成分との塩 |
EP2755637B1 (en) * | 2011-09-13 | 2020-08-12 | ISP Investments LLC | Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer |
WO2014135545A1 (en) | 2013-03-05 | 2014-09-12 | Sandoz Ag | Solid dispersion comprising amorphous lorcaserin hydrochloride |
WO2015011113A1 (en) | 2013-07-22 | 2015-01-29 | Sandoz Ag | Formulations containing amorphous dapagliflozin |
PT107568B (pt) * | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
-
2020
- 2020-08-28 MX MX2022002280A patent/MX2022002280A/es unknown
- 2020-08-28 JP JP2022513160A patent/JP2022546411A/ja active Pending
- 2020-08-28 AU AU2020336471A patent/AU2020336471A1/en active Pending
- 2020-08-28 KR KR1020227007093A patent/KR20220054311A/ko active Search and Examination
- 2020-08-28 CA CA3152307A patent/CA3152307A1/en active Pending
- 2020-08-28 CN CN202080060511.6A patent/CN114302710A/zh active Pending
- 2020-08-28 WO PCT/US2020/048429 patent/WO2021041824A1/en active Application Filing
- 2020-08-28 US US17/635,815 patent/US20220304936A1/en active Pending
- 2020-08-28 EP EP20768820.1A patent/EP4021416A1/en active Pending
- 2020-08-28 BR BR112022003812A patent/BR112022003812A2/pt unknown
-
2022
- 2022-02-27 IL IL290943A patent/IL290943A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3152307A1 (en) | 2021-03-04 |
EP4021416A1 (en) | 2022-07-06 |
KR20220054311A (ko) | 2022-05-02 |
JP2022546411A (ja) | 2022-11-04 |
CN114302710A (zh) | 2022-04-08 |
US20220304936A1 (en) | 2022-09-29 |
IL290943A (en) | 2022-04-01 |
MX2022002280A (es) | 2022-04-25 |
AU2020336471A1 (en) | 2022-03-24 |
WO2021041824A1 (en) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019003630A2 (es) | Composiciones no proteínicas de toxina clostridial | |
MX2021003558A (es) | Sistemas de suministro polimerico de accion prolongada. | |
BR112016028961A2 (pt) | composições compreendendo fibras obtidas por via eletro-hidrodinâmica para administração de dosagens específicas de uma substância ativa à pele ou mucosa | |
BR112018010683B8 (pt) | Método para produzir uma composição de glucano | |
BR112018015824A2 (pt) | composições para higiene pessoal | |
CL2019001447A1 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos. | |
BR112018002414A2 (pt) | sistema de distribuição de polímero líquido para administração prolongada de fármacos | |
BR112018074726A2 (pt) | sistema para distribuir um produto | |
MX2018005206A (es) | Composicion farmaceutica que comprende fibras obtenidas electrohidrodinamicamente y que tiene tiempo de residencia mejorado en el sitio de aplicacion. | |
MX2018000894A (es) | Composicion de fragancia a base de agua, dispositivo de suministro de fragancia, y metodo para proporcionar un perfume de larga duracion. | |
WO2018141941A3 (en) | Methods and systems for improving stability of pre-vapor formulations of e-vaping devices | |
BR112019008239A2 (pt) | formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos | |
BR112018001486A2 (pt) | ?composição de limpeza em barra, processo para preparar a composição, método para reduzir atividade antimicrobiana em uma superfície e uso da composição? | |
MX2019004973A (es) | Moduladores de ror gamma. | |
BR112018003516A2 (pt) | moléculas tendo utilidade pesticida, e intermediários, composições e processos rela-cionados às mesmas | |
BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
BR112015019580A2 (pt) | processo para preparar uma solução aquosa, solução aquosa, medicamento, alimento, ingrediente de alimento ou suplemento alimentício e método para reduzir a assimilação calórica | |
BR112022002289A2 (pt) | Composições de curativo líquido e seus usos veterinários | |
BR112022005148A2 (pt) | Sistemas de injeção e métodos de uso dos mesmos | |
BR112018070626A2 (pt) | formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição | |
BR112017017643A2 (pt) | formulação farmacêutica tópica | |
BR112022003812A2 (pt) | Dispersão sólida amorfa, produto, e, métodos para administrar um ingrediente farmacêutico ativo a uma pessoa ou animal não humano e para formar uma dispersão sólida amorfa de um ingrediente farmacêutico ativo | |
BR112017015452A2 (pt) | formulação farmacêutica | |
EP4279137A3 (en) | Oral pharmaceutical composition and method for producing particulate formulation comprising composition | |
MX2022006502A (es) | Composiciones farmaceuticas. |